Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (181-190 of 574) with videos related to

Pageof 58
Sort By:
Cancer Medicine|October 25, 2022
Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trialJiahui Zhang, Weili Kong, Pingzhao Hu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?Charles Lim, Mike Sung, Frances A Shepherd, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|July 27, 2019
Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort studyDaniel J Lee, Caitlin P McMullen, Andrew Foreman, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 28, 2020
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world dataAli Vedadi, Sharara Shakik, M Catherine Brown, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controlsChristen Gray, Eleanor Ralphs, Matthew P Fox, et al.
Carcinogenesis|September 11, 2008
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma riskRihong Zhai, Geoffrey Liu, Kofi Asomaning, et al.
JTO Clinical and Research Reports|January 2, 2026
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLCBeatriz Jimenez Munarriz, Sameena Khan, Katrina Hueniken, et al.
Pageof 58

Showing results (181-190 of 574) with videos related to

Sort By:
Pageof 58
Cancer Medicine|October 25, 2022
Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trialJiahui Zhang, Weili Kong, Pingzhao Hu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Patients with Advanced Non-Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?Charles Lim, Mike Sung, Frances A Shepherd, et al.
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|July 27, 2019
Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort studyDaniel J Lee, Caitlin P McMullen, Andrew Foreman, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 28, 2020
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world dataAli Vedadi, Sharara Shakik, M Catherine Brown, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controlsChristen Gray, Eleanor Ralphs, Matthew P Fox, et al.
Carcinogenesis|September 11, 2008
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma riskRihong Zhai, Geoffrey Liu, Kofi Asomaning, et al.
JTO Clinical and Research Reports|January 2, 2026
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLCBeatriz Jimenez Munarriz, Sameena Khan, Katrina Hueniken, et al.
Pageof 58